Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 11/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 8/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6730985 | 0.91 | PTPN1 (0.44) | PTPN1 | |
| SCHEMBL6736222 | 0.91 | PTPN1 (0.62) | PTPN1EGFRSRCSTAT3 | |
| SCHEMBL6736467 | 0.89 | PTPN1 (0.55) | PTPN1EGFRSRCSTAT3 | |
| SCHEMBL6730813 | 0.82 | CYP1A2 (0.37) | — | |
| SCHEMBL6736759 | 0.81 | PTPN1 (0.51) | PTPN1 | |
| SCHEMBL6734060 | 0.81 | NUDT1 (0.34) | PTPN1 | |
| SCHEMBL7083770 | 0.80 | PTPN1 (0.45) | PTPN1STAT3 | |
| SCHEMBL6731794 | 0.80 | PTPN1 (0.42) | PTPN1EGFRSRC | |
| SCHEMBL6730748 | 0.77 | PTPN1 (0.55) | PTPN1EGFRSRCSTAT3 | |
| SCHEMBL6735264 | 0.77 | PTPN1 (0.40) | PTPN1STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073709-A1 | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2003-04-17 | — | — | US | claimed |
| US-20020035272-A1 | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-21 | — | — | US | claimed |
| US-6103708-A | USEFUL IN TREATING METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-08-15 | — | — | US | claimed |
| US-6683107-B2 | THERAPY OF METABOLISM DISORDERS | WYETH | 2004-01-27 | — | — | US | disclosed |
| US-20030073709-A1 | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2003-04-17 | — | — | US | disclosed |
| US-6451845-B1 | ANTIDIABETIC AGENTS | WYETH | 2002-09-17 | — | — | US | disclosed |
| US-20020035272-A1 | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-21 | — | — | US | disclosed |
| US-6248764-B1 | ANTIDIABETIC AGENT; HYPOGLYCEMIC AGENT | AMERICAN HOME PRODUCTS CORPORATION | 2001-06-19 | — | — | US | disclosed |
| US-6103708-A | USEFUL IN TREATING METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073709-A1 | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | GPR119, INSR, FFAR3 | PTPN1 178/4885EGFR 536/4885SRC 2498/4885 |
| US-20020035272-A1 | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | INSR, GPR119, FFAR3 | PTPN1 200/4885EGFR 644/4885SRC 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.